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ABSTRACT
Objectives: To analyze the outcomes of pregnancies and risk factors in Chinese women with different stages of systemic 
lupus erythematosus (SLE).
Material and methods: A total of 55 conceptions in 52 patients with SLE between Jan 2007 and Jan 2019 were retrospected 
systematically from a general hospital graded 3A in China. Medical records provided us a good way to retrieve the clinical 
parameters and lab data of patients. 
Results: Pregnant women with SLE activity had significant hyperimmunoglobulin, hypocomplement, low platelet counts, 
high erythrocyte sedimentation rate, C-reactive protein and 24-h urine protein. Hydroxychloroquine had been used to reduce 
the rates of SLE activity in pregnant women. Logistic regression analysis showed low platelet counts, hypocomplement and 
24-h urine protein were significantly correlated with fetal loss. Compared to those in stable stage, the active SLE patients 
have more risks of hypertensive disorders of pregnancy, thrombocytopenia, lupus nephritis and placental infarction, and 
have worse fetal outcomes, including the higher rate of fetal loss, preterm and asphyxia neonatorum.
Conclusions: Different stages of SLE during pregnancy are closely related to maternal and fetal outcomes. It is imperative 
to provide SLE women with pregnancy consultation and regular multispecialty care.
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INTRODUCTION
Systemic lupus erythematosus (SLE) is a disease involv-
ing autoimmune system, with a morbidity of 4–35 cases per 
100 thousand people annually, which preponderantly af-
fects women considerably more often than men, particularly 
women of reproductive age [1]. As multidisciplinary man-
agements have increasingly involved and the treatments 
of SLE pregnant women have been improved, the preg-
nancy outcomes have significantly ameliorated for decades 
[2]. But such patients are still considered to have high-risk 
pregnancies. The general trend shows that pregnancy in 
patients with SLE tend to have higher maternal mortal-
ity, exacerbations of disease activity, fewer live births and 
more complications during pregnancy, including a higher 
risk of preeclampsia/eclampsia, C-section, prematurity, in-
trauterine growth restriction (IUGR), neonatal death and 
post-partum infection [3–6]. While SLE has many systemic 
effects, the fertility of these patients is typically unaltered 
from the general population [3]. 
Given the high popularity of SLE among women and its 
damage to maternal and infant health, more researches are 
needed to have better comprehensions about the impacts 
of active disease on the safety of mother and fetus as the 
data remain inconclusive [7]. This study aimed to evalu-
ate factors associated with clinical outcome of active and 
non-active SLE in Chinese pregnant patients. 
MATERIAL AND METHODS
A retrospective analysis about the medical records 
of 55 sequential conceptions in 52 patients with SLE in 
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a general hospital graded 3A from Jan 2007 to 
Jan 2019 was carried out. The diagnosis of SLE is based 
on the revised criteria formulated by the American Col-
lege of Rheumatology. Multiple gestations and elective 
terminations during the first trimester for personal rea-
sons were excluded. This study was authorized from the 
Ethics Committee and received permission to acquire 
clinical parameters from the Medical Director affiliated 
to Lishui People’s Hospital. The whole of patient informa-
tion was kept confidential.  
Patients’ clinical characteristics were gathered with lab 
information from medical records. Lab data consisted of 
hemoglobin (HB), white blood cell (WBC), platelet (PLT), 
erythrocyte sedimentation rate (ESR), C-reactive protein 
(CRP), urine protein (PRO), 24-hour urine protein (24-h PRO), 
albumin (ALB), serum creatinine (CR), blood urea nitrogen 
(BUN), totalcholesterol (TC), triglyceride (TG), low density 
lipoprotein cholesterol (LDL-C), high density lipoprotein 
cholesterol (HDL-C) along with immunologic information 
including immuneglobulin A, immuneglobulin M, immune-
globulin G, complement 3 (C3), complement 4 (C4), antinu-
clear antibodies (ANA), anti-ds DNA antibodies (anti-dsDNA), 
anti-Smith antibody (anti-Sm), anti-Ro/SSA antibodies, 
anti-La/SSB antibodies, antiphospholipid antibodies (aPL). 
All laboratory tests were performed using standardised 
methods. The placentas were sent for pathological exami-
nation after delivery. 
The disease activity of SLE was made an appropri-
ate evaluation based on the SLE Disease Activity Index 
2000 (SLEDAI-2K) [8]. Patients were categorized into two 
groups, according to SLEDAI score: active SLE group (≥ 5) 
and non-active SLE group (≤ 4). 
Maternal outcomes included hypertensive disor-
ders of pregnancy (HDP), gestational diabetes mellitus 
(GDM), anemia, thrombocytopenia, lupus nephritis, pre-
mature rupture of membranes (PROM), oligohydramnios, 
postpartum haemorrhage (PPH), placental infarction 
and chorioamnionitis in pathological diagnosis. Preg-
nancy-induced hypertension (PIH) was a state of blood 
pressure ≥ 140/90 mmHg on two occasions apart at 
least ≥ 6 hours observed after the 20th gestational week. 
Proteinuria > 0.3 g/L/day with hypertension was named 
pre-eclampsia. In this study, PIH and pre-eclampsia were 
both classified as HDP for a small number of cases. When 
hemoglobin is less than 100 g/L during pregnancy, ane-
mia was defined. Thrombocytopenia was defined the 
count of platelet less than 100 × 109/L. When amniotic 
fluid index was less than 5cm or amniotic fluid verti-
cal depth was less than 2cm, oligohydramnios was di-
agnosed. PPH was defined as the loss of blood within 
24 hours after delivery, with the amount of bleeding was 
500 mL or more.  
Fetal outcomes included fetal loss, prematurity, IUGR 
and asphyxia neonatorum. Fetal loss referred to pregnancy 
failure due to spontaneous abortion, therapeutic abor-
tion, stillbirth or neonatal death. Preterm birth referred 
to live birth between 28 weeks and less than 37 gesta-
tional weeks. IUGR was defined as a 10% lower limit for 
birth weight below the CI of the normal gestational weight 
curve. An Apgar score > 7 was considered normal, while 
a score ≤ 7 should be considered as asphyxia.
Statistical analysis
Statistical analysis was performed with SPSS version 
19.0. The medical data were expressed as means ± SD or 
frequencies. The count data were compared using the 
χ2 test. Comparisons of measurement data were per-
formed using the Student’s t-test appropriately. Logis-
tic regression analyses were not only used to compare 
multiple factors but also calculated the ORs of 95% CIs 
for maternal-infant outcomes. P < 0.05 was considered 
statistically significant. The missing data were processed 




There was a total of 52 patients with 55 gestations 
in our study, including 26 cases with active SLE and 
29 cases with non-active SLE. The average age at diagno-
sis of SLE was 22.71 ± 3.81 years (range, 14 to 31 years). 
The exhibitions of the general characteristics were dis-
played in Table 1. Mean ages, body mass index (BMI) and 
living area were not significantly different between the 
two cohorts as the same as the mean duration of SLE 
and the incidence of caesarean section. There were no 
significant differences in comorbid conditions including 
diabetes and/or hypertension diagnosed pre-pregnancy 
between active and non-active SLE patients. The pro-
portion of women who had a history of spontaneous 
abortion and nulliparity was not significantly different 
between the two groups. 
Most of cases both from active and non-active SLE 
groups were treated with low-dose glucocorticoids(GC), 
prednisone dose ranged from 2.5 to 25 mg. There were three 
cases in the active phase treated with immunosuppres-
sants, including azathioprine, tacrolimus and cyclosporine 
A. Compared to non-active SLE pregnancies, patients with 
active SLE had a significant lower proportion taking hydroxy-
chloroquine (HCQ) with dose of 200 mg/d (42.3% vs 69.0%, 
p < 0.05). Aspirin (100 mg/d) was taken by patients with 
positive aPL antibodies. Only two patients with HDP in the 
quiescent phase of SLE used low-molecular-weight-heparin 
(LMWH) during their pregnancy.
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Comparison of laboratory indexes of SLE in 
different stages
In the present study, significant differences in autoanti-
bodies were observed between the active and non-active 
SLE groups, including anti-ds DNA (53.8% vs 24.1%), anti-Sm 
(50.0% vs 24.1%), anti-Ro/SSA (84.6% vs 58.6%). Compared 
to non-active SLE pregnancies, patients with active SLE had 
significant hyperimmunoglobulin (57.7% vs 20.7%),but had 
hypocomplement (76.9% vs 24.1%). Low PLT, high ESR, CRP 
and 24-h PRO during pregnancy were significantly associ-
ated with SLE activity. No other significant differences were 
found in the laboratory findings between the two cohorts 
(Tab. 2).
Risk factors affecting fetal loss 
Based on the results of single factor analyses, fetal loss 
was correlated with presence of taking hydroxychloroquine 
(HCQ), positive rate of anti-ds DNA, anti-Sm and anti-Ro/SSA, 
hyperimmunoglobulin, hypocomplement, low PLT, high 
ESR, CRP and 24h PRO. As show in Table 3, when factors 
related to fetal loss in univariate analysis were used as inde-
pendent variables in multivariate logistic regression analysis, 
it was found that low PLT, hypocomplement and high 24-h 
PRO were significantly correlated with fetal loss. 
Pregnancy outcomes                                            
HDP was diagnosed in 50.0% of the active SLE pa-
tients. The risk of HDP (OR 4.588, 95% CI 1.084 to 19.416) 
remained high after adjusting for confounding factors. The 
incidence of thrombocytopenia and lupus nephritis in wom-
en with active SLE was significantly higher than those in the 
Table 1. General clinical features of active and inactive systemic 
lupus erythematosus (SLE) patients in pregnancy
Variables Active SLE Non-active SLE P
Age [yrs, mean ± SD] 28.04 ± 3.97 30.14 ± 3.94 0.054
BMI [kg/m2 mean ± SD] 23.94 ± 3.39 23.30 ± 2.79 0.447
0.051Nulliparity, n (%) 20 (76.9%) 14 (48.3%)
Region, n (%)
City 12 (46.2%) 17 (58.6%) 0.423
Rural 14 (53.8%) 12 (41.4%)
Duration of SLE [years, 
mean ± SD] 5.85 ± 3.66 6.72 ± 2.87 0.324
History of spontaneous 
abortion, n (%)
With 15 (57.7%) 15 (51.7%) 0.657
Without 11 (42.3%) 14 (48.3%)
Prepregnancy diabetes, 
n (%) 1 (3.8%) 0 0.473
Prepregnancy 
hypertension, n (%) 4 (15.4%) 2 (6.9%) 0.406
Cesarean section, n (%) 14 (53.8%) 20 (69.0%) 0.279
Drugs taken at the onset 
of pregnancy
Prednisone, n (%) 25 (96.2%) 26 (89.7%) 0.970
Prednisone dose (mg/d) 12.88 ± 6.19 10.26 ± 4.93 0.086
HCQ, n (%) 11 (42.3%) 20 (69.0%) 0.022
Immunosuppressants, 
n (%) 3 (11.5%) 0 0.099
Aspirin, n (%) 7 (26.9%) 5 (17.2%) 0.238
LMWH, n (%) 0 2 (6.9%) 0.173
SLE — systemic lupus erythematosus; SD — standard deviation; BMI — body 
mass index; HCQ — hydroxychloroquine; LMWH — low molecular weight heparin
Table 2. Comparison of laboratory indexes of systemic lupus 
erythematosus (SLE) patients in different states
Variables Active SLE Non-active SLE P
ANA, n (%) 26 (100.0%) 28 (96.6%) 0.339
anti-dsDNA, n (%) 14 (53.8%) 7 (24.1%) 0.024
anti-Sm n (%) 13 (50.0%) 7 (24.1%) 0.047
anti-Ro/SSA, n (%) 22 (84.6%) 17 (58.6%) 0.034
anti-La/SSB, n (%) 7 (26.9%) 4 (13.8%) 0.224
aPL, n (%) 10 (38.5%) 5 (17.2%) 0.129
Hyperimmunoglobulin, 
n (%) 15 (57.7%) 6 (20.7%) 0.006
 A, n (%) 9 (34.6%) 2 (6.9%) 0.017
 M, n (%) 8 (30.8%) 2 (6.9%) 0.035
 G, n (%) 11 (42.3%) 3 (10.3%) 0.012
Hypocomplement, 
n (%) 20 (76.9%) 7 (24.1%) < 0.001
 C3, n (%) 17 (65.4%) 6 (20.7%) 0.001
C4, n (%) 16 (61.5%) 7 (24.1%) 0.005
HB [g/L] 109.15 ± 12.66 111.17 ± 16.95 0.622
WBC [×109/L] 8.06 ± 2.79 9.32 ± 3.58 0.155
PLT [×109/L] 125.23 ± 51.20 197.59 ± 61.57 < 0.001
ESR [mm/h] 32.10 ± 13.51 20.24 ± 8.73 < 0.001
CRP [mg/L] 15.00 ± 13.76 8.69 ± 8.92 0.045
PRO, n (%) 16 (61.5%) 12 (41.4%) 0.180
24-h PRO [g/24 h] 0.92 ± 1.16 0.34 ± 0.24 < 0.001
ALB [g/L] 30.65 ± 2.88 32.81 ± 2.76 0.701
CR [umol/L] 52.62 ± 13.99 49.79 ± 10.78 0.157
BUN [mmol/L] 3.80 ± 1.10 3.54 ± 1.38 0.305
TC [mmol/L] 3.48 ± 1.12 3.04 ± 0.72 0.082
TG [mmol/L] 4.90 ± 0.97 4.43 ± 0.85 0.063
LDL-C [mmol/L] 2.55 ± 0.55 2.49 ± 1.00 0.760
HDL-C [mmol/L] 1.47 ± 0.38 1.55 ± 0.38 0.399
SLE — systemic lupus erythematosus; ANA — antinuclear antibodies; HB 
— hemoglobin; WBC — white blood cell; PLT — platelet; ESR — erythrocyte 
sedimentation rate; CRP — C-reactive protein; PRO — urine protein; 24-h PRO 
— 24-hour urine protein; ALB — albumin; CR — serum creatinine; BUN — blood 
urea nitrogen; TC — totalcholesterol; TG — triglyceride
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other cohort, and the risks of thrombocytopenia (OR 10.316, 
95% CI 1.172 to 90.780) and lupus nephritis (OR 1.846, 95% 
CI 0.718 to 4.997) remained unchanged after adjusting for 
confounding factors. Placental infarction was commonly 
founded among active SLE patients, and the rate was 3.58-
fold higher in the group of active SLE than that in non-active 
SLE. Significant differences in the remaining manifestations 
of maternal outcomes, including GDM, anemia, PROM, oligo-
hydramnios, PPH and chorioamnionitis, were not observed 
between the two groups. Peripartum infection was not oc-
curred in two groups, except one SLE patient in the quiescent 
phase. Maternal deaths did not occur in either groups. 
Fetal loss occurred in four cases in the active SLE phase. 
Two cases were accompanied by lupus nephritis (one case 
with intrauterine fetal death and the other with neonatal 
death). The rest of two cases with therapeutic abortion were 
in relation to immunosuppressant therapy. After adjusting 
for confounding factors, the total fetal loss rate (OR 1.808, 
95% CI 0.670–1.974) of patients with active SLE was higher 
than that of patients with inactive SLE. In the two cohorts, 
preterm births accounted for 42.3% and 20.7%, respectively. 
The adjusted OR remained high for outcome (OR 3.833, 95% 
CI 1.124 to 13.076). Furthermore, we also observed higher 
rate of asphyxia neonatorum for pregnant women with dis-
ease activity. The Apgar score (1 min) in active SLE group was 
remarkably lower than that of the other group. It was ob-
served in 26.9% and 6.9% of pregnancies, respectively, in the 
two cohorts. When the confounding factors were adjusted, 
the risk of asphyxia neonatorum (OR 6.300, 95% CI 1.158 to 
34.262 was still high. Finally, significant difference in the rate 
of IUGR was not observed between the two cohorts (Tab. 4). 
DISCUSSION
Most of studies show the increased flare rates by 25–65% 
[7, 9, 10]. Other researches have evaluated different out-
comes of lupus flares during pregnancy and shown a low 
incidence of flare (19.4–25%). In this study, 26 (47.3%) of the 
patients experienced SLE activity during pregnancy. Most 
of the disease activity observed in these patients ranged 
from mild to moderate, with new skin-joint changes. The 
active period of the disease mainly occurred after the sec-
ond trimester.
Table 3. Multiple factor logistic regression analysis for Risk factors affecting fetal loss
Variables B SE Wald DF p value OR
95% CI of OR
Lower Upper
24-h urine protein -5.635 2.573 4.797 1 0.029 0.004 0.000 0.553
Platelet counts 0.029 0.014 4.082 1 0.043 1.029 1.001 1.059
Hypocomplement C3/C4 5.122 2.291 5.000 1 0.025 6.795 1.882 14.938
SE — standard error; DF — degrees of freedom; CI — confidence interval; OR — odds ratio; B — regression coefficient
Table 4. Comparison of pregnancy outcomes between active SLE and inactive SLE patients
Pregnancy outcome Active SLE Non-active SLE P OR (95%CI)
Maternal outcome
HDP 13 (50.0%) 6 (20.7%) 0.048 4.588 (1.084–19.416)
GDM 1 (3.8%) 1 (3.4%) 0.937 1.120 (0.067–18.861)
Anemia 7 (26.9%) 7 (24.1%) 0.813 1.158 (0.344–3.899)
Thrombocytopenia 7 (26.9%) 1 (3.4%) 0.014 10.316 (1.172–90.780)
Lupus nephritis 4 (15.4%) 0 0.028 1.846 (0.718–4.997)
PROM 11 (42.3%) 9 (31.0%) 0.415 1.630 (0.539–4.927)
Oligohydramnios 6 (23.1%) 5 (17.2%) 0.739 1.440 (0.382–5.428)
PIH 3 (11.5%) 2 (6.9%) 0.550 1.761 (0.270–11.467)
Placental infarction 15 (57.7%) 8 (27.6%) 0.031 3.580 (1.161–11.040)
Chorioamnionitis 11 (42.3%) 14 (48.3%) 0.788 0.786 (0.271–2.281)
Fetal outcome
Fetal loss 5 (19.2%) 0 0.019 1.808 (0.670–1.970)
Premature 11 (42.3%) 6 (20.7%) 0.038 3.833 (1.124–13.076)
IUGR 6 (23.1%) 4 (13.8%) 0.295 2.344 (0.571–9.621)
Asphyxia neonatorum 7 (26.9%) 2 (6.9%) 0.029 6.300 (1.158–34.262)
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In order to avoid adverse maternal and fetal outcomes 
during pregnancy, rational and standardized drug treatment 
was very important. GC, especially prednisone, had been 
the hallmark medication for SLE and were especially the 
more widely used therapy to control mild–severe flares of 
SLE [14]. However, during pregnancy, drug dose should be 
minimised as much as possible, high dose should be taken 
in a short time during disease flare, and drug dose must be 
administered during delivery [2, 15]. In general, the basis for 
the use of different dosages of GC in a specific clinical set-
ting in SLE is essentially empirical. In our sample, 25 (96.2%) 
pregnant women with SLE in active phase and 26 (89.7%) 
patients in non-active phase were treated with low-dose 
prednisone dose, ranged from 2.5 to 25 mg. 
HCQ was shown to reduce the rates of lupus fares in 
pregnancy and was widely applied in the treatment of SLE 
in recent years and has a good reputation in controlling 
skin complications from SLE [11, 16]. Our prevalence usage 
of HCQ was 42.3% in active phase and 69% in non-active 
phase, which was higher than that prescribed from 18% 
to 32.2% in Spain [17],but close to 55% in the US [18]. 
The possible reasons listed as follows: Firstly, our patients 
had the scope from Jan 2007 to Jan 2019. Although on the 
early years, HCQ was not used in our country extensively, 
case data were mainly concentrated in the past 10 years with 
HCQ used widely. Secondly, in China, when patients with SLE 
entered the stage of fertility, they were advised to accept 
management not only from obstetricians but also from 
rheumatologists, who would prescrib HCQ more frequently. 
Durcan et al. [19] found the SLE patients had abnormal 
lipoproteins, including a decrease in HDL and an increase in 
LDL, and suggested that HDL and LDL can be used as one of 
the important parameters to evaluate the disease activity. 
In our study, there was no obvious difference in lipid and 
lipoproteins between two groups. This finding might be due 
to the less cases in our study. In the follow-up study, we will 
conduct a multicenter study and bring more cases into our 
groups to obtain more data.   
The caesarean section surgery was accepted by 
34 (61.8%) patients in our study. The absolute rate was 
surprisingly high in both groups, and it was much higher 
than that reported in most previous studies, but lower 
than that of another Chinese study [15, 20]. SLE was still a risk 
factor for maternal and fetal outcomes. Most SLE women 
were inclined to undergo cesarean to terminate pregnancy, 
which was mainly because doctors and patients preferred 
elective cesarean to prevent complications closely related 
to SLE during birth. 
Multivariable analysis showed that fetal loss correlated 
with low PLT, hypocomplement and 24 h PRO in the present 
study, which was in line with the previous reports [21, 22]. 
It directly confirmed the adverse effect of SLE activity on 
fetal outcome. The results of our study confirmed that al-
most one third of SLE pregnant women had obvious HDP 
complications, diagnosed in 50.0% of the women with active 
SLE and 20.7% of the women with non-active SLE. The OR 
remained significant, even after adjusting for confounding 
factors. It was in line with the reported literatures [9, 23]. 
Previous studies demonstrated that thrombocytopenia and 
lupus nephritis were significantly associated with adversely 
maternal-infatal outcomes [23–25]. Based on our findings, 
it was demonstrated as important risk factors for severe 
obstetric outcomes.  
Additionally, placental infarction occurred in nearly 42% 
pregnant women with SLE, and especially 3.58-fold higher in 
the patients with active SLE than the others. This finding was 
consistent with the result described in the study Magid MS 
et al. [26]. Some research mainly focused on the risk factors 
of poor fetal outcomes in different phases of SLE. Zhan et al. 
[27] also carried on a retrospective study of 263 pregnant 
patients with SLE, which showed that patients with active 
lupus had a 12.4-fold higher risk of fetal loss. Moreover, Ku 
et al. [28] discovered an association between active disease 
and live births. In our study, the total fetal loss rate was 
higher in the active SLE patients (OR 1.808, 95% CI 0.670 to 
1.974 ,which was lower than the previous reports and prob-
ably due to the more use of GC and HCQ. Furthermore, in our 
study, a higher rate of preterm and asphyxia neonatorum 
was observed in the active SLE group (42.3% and 26.9% , 
respectively) . The adjusted OR remained high for outcomes 
(OR = 3.833 and OR = 6.300, respectively). The results was 
similar to several other studies [29, 30].  
Limitations
There were several limitations to our study. Firstly, we 
had some data loss because it was a retrospective study. 
Secondly, patients were usually referred to our institution 
after the second trimester and lacked information at the pre 
and beginning of pregnancy. So, in our work, there were 
no cases in the early abortion, whether spontaneous or 
therapeutic. Thirdly, our single-center study might have had 
bias. Additionally, most patients with SLE during pregnancy 
did not have postpartum visits in our hospital. Finally, since 
many patients entered this study only after pregnancy, we 
did not have information to review the activity of the dis-
ease before conception and to define whether conception 
increased the risk of activity or not.
CONCLUSIONS
In conclusion, the risks of HDP, thrombocytopenia, lu-
pus nephritis and placental infarction increase significantly 
in active SLE women during pregnancy. In addition, SLE in 
active stage leads to higher rates of fetal loss, premature 
delivery and asphyxia neonatorum. Therefore, we suggest 
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that when these patients enter the stage of fertility, par-
ticularly in active period, they are still considered to have 
high-risk pregnancies, should have full access to precon-
ception counselling, and should be ideally managed under 
the coordinated care of obstetricians, rheumatologists and 
other specialists as needed. 
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